Skip to main content
Premium Trial:

Request an Annual Quote

Norwegian DNA Analysis Company iSentio Raises $1.5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian DNA analysis company iSentio today announced it has raised $1.5 million to grow its sales and marketing efforts and accelerate development of new application areas for its RipSeq software.

The funding was led by existing and new investors, including Norwegian seed capital fund, Sarsia Seed, a new investor.

In a statement, the company said that it has had a successful market introduction of its web-based sequence RipSeq software for identifying multiple bacteria after direct sequencing of clinical patient samples. The software is used in hospitals in both Europe and the US.

The new funding was to done to capitalize on the momentum from the launch and will allow the company to expand its presence and address new markets, iSentio CEO Bjarte Karlsen said in a statement.

iSentio also named a new board chairperson, Siri Fürst, who has held various managerial positions at Hafslund, Hafslund Nycomed, and Nycomed Pharma. She was also CEO of DiaGenic.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.